ASP Isotopes Inc.
ASPI Nasdaq Miscellaneous Chemical Products Financials FY2022βFY2025
What ASP Isotopes Inc. does
No business description yet.
- Legal name
- ASP Isotopes Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K Β· Apr 10, 2026
- Accession Β· CIK
- 0001193125-26-151294
0001921865
Revenue and margins
ASP Isotopes Inc. had $23.8M of revenue in fiscal 2025, up 475.5% on the year before.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was β$47.4M in fiscal 2025, β198.9% of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
ASP Isotopes Inc. returned $0.0M to shareholders in fiscal 2025. The diluted share count rose 49.1%.
Balance sheet
Cash, debt and the ratios that show how comfortably ASP Isotopes Inc. can carry it.
| Fiscal year end | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Cash and short-term investments | $2.4M | $7.9M | $61.9M | $327M |
| Debt incl. finance leases | β | β | $2.4M | $2.1M |
| Debt / equity | β | β | 0.0x | 0.0x |
| Interest coverage | β | β135.4x | β101.8x | β104.2x |
| Current ratio | 1.7x | 1.9x | 9.3x | 12.2x |
| Quick ratio | 1.7x | 1.9x | 9.3x | 12.2x |
| Total assets | $12.5M | $27.5M | $94.3M | $498M |
| Total liabilities | $2.7M | $8.7M | $43.2M | $235M |
| Shareholders' equity | $9.8M | $16.3M | $47.9M | $204M |
| Net debt (β = net cash) | β | β | β$59.5M | β$325M |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
| Test | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Net income is positive | β | β | β | β |
| Cash from operations is positive | β | β | β | β |
| Return on assets rose | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β |
| Debt fell relative to assets | β | β | β | β |
| Current ratio rose | β | β | β | β |
| Share count didn't rise | β | β | β | β |
| Gross margin rose | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β |
| F-score | β / 3 | β / 6 | 5 / 8 | 5 / 9 |
| Accruals ratio | β16.0% | β54.4% | β25.8% | β41.2% |
| Altman Z'' | β0.15 | β3.62 | 1.43 | 3.43 |
4 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $0.0M | $0.4M | $4.1M | $23.8M |
| Net interest income | $0.0M | β | β | β |
| Gross profit | $0.0M | $0.1M | $1.6M | $3.4M |
| Research and development | $1.3M | $0.8M | $3.1M | $12.4M |
| Operating income | β$5.1M | β$16.0M | β$26.4M | β$59.9M |
| Interest expense | $0.0M | $0.1M | $0.3M | $0.6M |
| Pretax income | β$4.9M | β$16.3M | β$32.3M | β$160M |
| Income tax | $0.0M | β$0.0M | $0.1M | $0.3M |
| Net income | β$4.9M | β$16.3M | β$32.4M | β$160M |
| Diluted EPS | β | β$0.49 | β$0.63 | β$2.11 |
| Diluted shares | β | 0.03B | 0.06B | 0.08B |
| Cash flow | ||||
| Cash from operations | β$2.9M | β$5.4M | β$16.7M | β$37.8M |
| Capital expenditure | $4.5M | $2.3M | $9.7M | $9.7M |
| Free cash flow | β$7.4M | β$7.7M | β$26.4M | β$47.4M |
| Depreciation and amortization | $0.0M | $0.0M | $0.5M | $1.9M |
| Stock-based compensation | $2.0M | $8.7M | $8.6M | $16.0M |
| Dividends paid | β | $0.0M | $2.8M | $0.0M |
| Dividends and buybacks | β | $0.0M | $2.8M | $0.0M |
| Balance sheet | ||||
| Cash and short-term investments | $2.4M | $7.9M | $61.9M | $327M |
| Total debt | β | β | $2.4M | $2.1M |
| Current assets | $3.3M | $10.5M | $65.7M | $400M |
| Current liabilities | $1.9M | $5.7M | $7.1M | $32.7M |
| Inventory | β | $0.0M | $0.1M | $1.1M |
| Property and equipment, net | $8.2M | $10.7M | $22.4M | $33.3M |
| Goodwill | $0.0M | $3.3M | $3.2M | $5.2M |
| Intangible assets | β | β | β | $0.7M |
| Total assets | $12.5M | $27.5M | $94.3M | $498M |
| Total liabilities | $2.7M | $8.7M | $43.2M | $235M |
| Preferred stock | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | $9.8M | $16.3M | $47.9M | $204M |
| Margins | ||||
| Gross margin | β | 32.1% | 38.6% | 14.3% |
| Operating margin | β | β3,704.8% | β636.0% | β251.2% |
| EBITDA margin | β | β3,696.2% | β624.6% | β243.2% |
| Net margin | β | β3,763.1% | β782.4% | β670.2% |
| FCF margin | β | β1,788.4% | β636.4% | β198.9% |
| Returns | ||||
| Return on capital employed | β48.3% | β73.4% | β30.2% | β12.9% |
| Return on equity | β50.4% | β124.8% | β101.0% | β126.8% |
| Return on assets | β39.6% | β81.4% | β53.2% | β54.0% |
| Return on tangible equity | β50.4% | β125.1% | β72.5% | β80.6% |
| Growth | ||||
| Revenue growth | β | β | 857.0% | 475.5% |
| Share count change | β | β | 68.4% | 49.1% |
| Financial health | ||||
| Debt / equity | β | β | 0.0x | 0.0x |
| Interest coverage | β | β135.4x | β101.8x | β104.2x |
| Current ratio | 1.7x | 1.9x | 9.3x | 12.2x |
| Quick ratio | 1.7x | 1.9x | 9.3x | 12.2x |
| Capital allocation | ||||
| Capex / revenue | β | 538.4% | 233.5% | 40.5% |
| Stock comp / revenue | β | 2,019.4% | 206.6% | 67.2% |
| Quality scores | ||||
| Piotroski F-score | β | β | 5.0 | 5.0 |
| Altman Z'' | β0.1 | β3.6 | 1.4 | 3.4 |
| Accruals ratio | β16.0% | β54.4% | β25.8% | β41.2% |
Source: SEC EDGAR XBRL filings (CIK 0001921865). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.